The ribosomal protein S6 in renal cell carcinoma: functional relevance and potential as biomarker
Authors:
Open Access
- 25 October 2015
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (1) , 418-432
Abstract
Inhibitors of the mTOR pathway, such as everolimus, are promising compounds to treat patients with renal cell carcinomas (RCCs). However, the precise mechanisms of action are far from clear, and biomarkers predicting the response to mTOR inhibitors are still missing. Here, we provide evidence that in RCCs the rpS6 protein is the major mediator of anti-tumoral effects exerted by everolimus. Inhibition of mTOR signaling results in substantially decreased clonogenicity and proliferation of RCC cells, but did not significantly induce apoptosis. Everolimus effectively blocked protein biosynthesis both in vitro and in a novel ex vivo tissue slice model using fresh vital human RCC tissue. Compared to other components of the mTOR pathway, phosphorylation of rpS6 was most effectively downregulated by everolimus. Importantly, siRNA-mediated downregulation of rpS6, but not of 4ebp1 or p27, abolished the inhibitory effects of everolimus on proliferation and protein synthesis. Moreover, we analyzed the tissue expression of phosphorylated rpS6 (p-rpS6) and non-phosphorylated rpS6 in a large collection of patients with RCCs (n=598 and n=548, respectively). Expression of both proteins qualified as independent negative prognostic markers with a substantially shorter survival of patients with RCCs exhibiting high levels of rpS6 and p-rpS6. Taken together, our functional studies identified rpS6 as a main mediator of the anti-tumoral activity of Everolimus. Therefore, further (pre-)clinical evaluations of rpS6 as a predictive marker for everolimus-based treatment for RCC patients are warranted. Finally, the combined detection of phosphorylated and non-phosphorylated rpS6 could represent a robust prognostic marker to identify patients with high risk RCCs.Keywords
This publication has 31 references indexed in Scilit:
- mTOR Signaling in Growth Control and DiseaseCell, 2012
- Sequential use of targeted agents in the treatment of renal cell carcinomaCritical Reviews in Oncology/Hematology, 2011
- Analysis of PTEN and HIF‐1α and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon‐αCancer, 2009
- Molecular mechanisms of mTOR-mediated translational controlNature Reviews Molecular Cell Biology, 2009
- Prognostic Value of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (TRAIL) and TRAIL Receptors in Renal Cell CancerClinical Cancer Research, 2009
- S6K1 Regulates GSK3 under Conditions of mTOR-Dependent Feedback Inhibition of AktMolecular Cell, 2006
- mTOR and cancer: insights into a complex relationshipNature Reviews Cancer, 2006
- The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALLBlood, 2006
- Upstream and downstream of mTORGenes & Development, 2004
- Damaged microtubules can inactivate BCL-2 by means of the mTOR kinaseOncogene, 2001